Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatril SCHEMBL121666 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL29494166 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL392920 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL5601069 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL14660450 | 0.98 | MME (0.95) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9470376 | 0.94 | MME (0.88) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL16624679 | 0.92 | MME (0.85) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7322664 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7329974 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9469895 | 0.89 | MME (0.80) | MMEPPARGPPARDKDM4EPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS GROUP, INC. | 2015-04-09 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2009127251-A1 | COMBINATIONS COMPRISING A RENIN INHIBITOR | NOVARTIS AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, IL5 | MME 3204/4885PPARG 1381/4885PPARD 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.